Abstract
Objective: To determine whether hMG offers an advantage over clomiphene citrate (CC) in achieving pregnancy after IUI with husband’s sperm. Design: Randomized prospective trial. Setting: Infertility patients in a university teaching hospital. Patient(s): Fifty-eight women under 39 years old undergoing ovulation induction before IUI. Intervention(s): The women were assigned randomly to one of two treatment groups. Patients in group I (CCHH) received CC for the first two cycles and hMG for the last two cycles. Patients in group II (HHCC) received hMG for the first two cycles and CC for the last two cycles. Main Outcome Measure(s): Cycle fecundity rates for the two treatment modalities were compared statistically with use of life-table analysis. Result(s): Of the 174 cycles studied, overall cycle fecundity rate was 11.11 (9 of 81 cycles) in the CCHH group and 10.75 (10 of 93 cycles) in the HHCC group. The difference was not statistically significant. The cycle fecundity rate was 14.44% (13 of 90 cycles) for cycles with CC and 7.14% (6 of 84) with hMG. The difference was not statistically significant. Conclusion(s): These data suggest that CC is an effective alternative to hMG in the population examined.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.